Loading...

Ceapro

OTCPK:CRPO.F
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CRPO.F
OTCPK
CA$29M
Market Cap
  1. Home
  2. US
  3. Materials
Company description

Ceapro Inc., a biotechnology company, engages in developing and commercializing functionally active ingredients in the United States, Canada, Germany, China, and internationally. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
CRPO.F Share Price and Events
7 Day Returns
9.2%
OTCPK:CRPO.F
1.1%
US Chemicals
0.5%
US Market
1 Year Returns
-36%
OTCPK:CRPO.F
-12.4%
US Chemicals
0.8%
US Market
CRPO.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ceapro (CRPO.F) 9.2% 1% - -36% -68.8% 123.9%
US Chemicals 1.1% 1.6% -6.5% -12.4% 18% 6.1%
US Market 0.5% -0.1% 1% 0.8% 37.5% 37.5%
1 Year Return vs Industry and Market
  • CRPO.F underperformed the Chemicals industry which returned -12.4% over the past year.
  • CRPO.F underperformed the Market in United States of America which returned 0.8% over the past year.
Price Volatility
CRPO.F
Industry
5yr Volatility vs Market

CRPO.F Value

 Is Ceapro undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ceapro. This is due to cash flow or dividend data being unavailable. The share price is $0.3.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ceapro's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ceapro's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:CRPO.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$-0.01
TSXV:CZO Share Price ** TSXV (2019-06-11) in CAD CA$0.38
United States of America Chemicals Industry PE Ratio Median Figure of 68 Publicly-Listed Chemicals Companies 17.79x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ceapro.

OTCPK:CRPO.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:CZO Share Price ÷ EPS (both in CAD)

= 0.38 ÷ -0.01

-44.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ceapro is loss making, we can't compare its value to the US Chemicals industry average.
  • Ceapro is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Ceapro's expected growth come at a high price?
Raw Data
OTCPK:CRPO.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -44.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
39.7%per year
United States of America Chemicals Industry PEG Ratio Median Figure of 49 Publicly-Listed Chemicals Companies 1.25x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ceapro, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ceapro's assets?
Raw Data
OTCPK:CRPO.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$0.29
TSXV:CZO Share Price * TSXV (2019-06-11) in CAD CA$0.38
United States of America Chemicals Industry PB Ratio Median Figure of 94 Publicly-Listed Chemicals Companies 2.03x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
OTCPK:CRPO.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:CZO Share Price ÷ Book Value per Share (both in CAD)

= 0.38 ÷ 0.29

1.29x

* Primary Listing of Ceapro.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ceapro is good value based on assets compared to the US Chemicals industry average.
X
Value checks
We assess Ceapro's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
  5. Ceapro has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CRPO.F Future Performance

 How is Ceapro expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Ceapro, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ceapro expected to grow at an attractive rate?
  • Ceapro's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Ceapro's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Ceapro's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:CRPO.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:CRPO.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 39.7%
United States of America Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 11.5%
United States of America Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 4.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:CRPO.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:CRPO.F Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OTCPK:CRPO.F Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 13 -2 -1
2018-12-31 12 -2 0
2018-09-30 10 0 -2
2018-06-30 12 2 -2
2018-03-31 12 2 -1
2017-12-31 13 2 -1
2017-09-30 12 2 1
2017-06-30 12 2 1
2017-03-31 13 2 2
2016-12-31 14 5 4
2016-09-30 15 7 7
2016-06-30 15 7 7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ceapro's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Ceapro is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:CRPO.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Ceapro Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CRPO.F Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OTCPK:CRPO.F Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 -0.01
2018-12-31 0.00
2018-09-30 -0.03
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.01
2017-09-30 0.01
2017-06-30 0.02
2017-03-31 0.03
2016-12-31 0.05
2016-09-30 0.11
2016-06-30 0.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ceapro will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Ceapro's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ceapro has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CRPO.F Past Performance

  How has Ceapro performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ceapro's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ceapro does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Ceapro's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ceapro's 1-year growth to the US Chemicals industry average as it is not currently profitable.
Earnings and Revenue History
Ceapro's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ceapro Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CRPO.F Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 12.52 -0.66 3.89 3.09
2018-12-31 11.59 -0.32 3.81 2.63
2018-09-30 10.09 -2.40 3.73 2.24
2018-06-30 11.57 -1.81 3.51 1.67
2018-03-31 12.01 -1.27 3.41 1.32
2017-12-31 12.93 -0.96 3.49 1.57
2017-09-30 12.38 0.81 3.34 1.69
2017-06-30 11.80 1.16 3.29 1.52
2017-03-31 12.79 2.42 3.12 1.15
2016-12-31 13.67 3.62 2.77 0.89
2016-09-30 14.68 6.95 2.49 0.65
2016-06-30 14.75 7.31 2.48 0.53
2016-03-31 13.02 6.33 2.59 0.83
2015-12-31 10.67 4.92 2.90 0.61
2015-09-30 9.29 1.57 2.95 0.47
2015-06-30 8.66 1.25 2.93 0.51
2015-03-31 8.65 1.22 2.76 0.46
2014-12-31 8.89 1.59 2.38 0.58
2014-09-30 8.33 1.39 1.99 0.76
2014-06-30 7.89 0.83 1.89 0.78
2014-03-31 6.47 -0.05 1.91 0.82
2013-12-31 6.52 0.18 1.95 0.73
2013-09-30 6.22 0.04 1.88 0.68
2013-06-30 5.51 -0.22 1.94 0.78
2013-03-31 5.99 -0.13 2.00 0.82
2012-12-31 5.17 -0.54 2.01 0.84
2012-09-30 5.51 -0.05 1.89 0.95
2012-06-30 5.75 -0.02 1.77 1.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ceapro has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ceapro has efficiently used its assets last year compared to the US Chemicals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ceapro improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ceapro's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ceapro has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CRPO.F Health

 How is Ceapro's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ceapro's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ceapro is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ceapro's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ceapro's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 12.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ceapro Company Filings, last reported 2 months ago.

OTCPK:CRPO.F Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 22.68 3.71 1.90
2018-12-31 23.22 0.64 1.84
2018-09-30 22.71 0.92 4.16
2018-06-30 22.31 1.12 5.41
2018-03-31 22.43 1.33 5.99
2017-12-31 22.54 1.53 6.17
2017-09-30 24.06 1.85 7.44
2017-06-30 23.67 2.09 7.08
2017-03-31 23.14 2.30 7.83
2016-12-31 22.40 2.53 9.15
2016-09-30 21.03 3.81 9.25
2016-06-30 10.91 3.99 0.91
2016-03-31 9.16 4.22 2.00
2015-12-31 7.88 4.44 1.68
2015-09-30 4.22 4.72 0.81
2015-06-30 3.09 4.65 0.55
2015-03-31 2.31 4.36 0.54
2014-12-31 2.09 3.47 0.27
2014-09-30 1.94 3.73 0.39
2014-06-30 1.24 3.97 0.71
2014-03-31 0.48 3.66 1.21
2013-12-31 0.24 3.19 1.95
2013-09-30 0.34 1.25 0.40
2013-06-30 0.21 1.32 0.36
2013-03-31 0.44 1.32 0.25
2012-12-31 0.01 1.35 0.27
2012-09-30 0.25 1.36 0.52
2012-06-30 0.37 1.41 0.34
  • Ceapro's level of debt (2.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (749% vs 2.1% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Ceapro's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Ceapro's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ceapro has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CRPO.F Dividends

 What is Ceapro's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ceapro dividends.
If you bought $2,000 of Ceapro shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ceapro's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ceapro's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:CRPO.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 54 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:CRPO.F Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ceapro has not reported any payouts.
  • Unable to verify if Ceapro's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ceapro's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ceapro has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ceapro's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ceapro afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ceapro has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CRPO.F Management

 What is the CEO of Ceapro's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gilles Gagnon
COMPENSATION CA$555,000
AGE 64
TENURE AS CEO 6.9 years
CEO Bio

Mr. Gilles R. Gagnon, M.Sc., MBA, ICD.D, serves as the President of Spectrum Pharma Canada Inc. (Spectrum Canada). Mr. Gagnon has been Chief Executive Officer and President of Ceapro Inc. since July 1, 2012 and served as its Acting Chief Executive Officer from July 4, 2008 to July 1, 2012. His extensive managerial experience, especially in mergers and acquisitions, as well as his inside knowledge of the pharma world aid Ceapro in executing its growth strategy. He is a consultant to several companies in the biopharmaceutical and healthcare fields. He spent 25 years in the management of healthcare related organizations in both hospital administration (8 years) and in the pharmaceutical industry (17 years). He served as the President and Chief Executive Officer of Æterna Zentaris Inc. (also known as AEterna Laboratories, Inc) until April 9, 2007. From 1999 to 2007, He was with Aeterna Zentaris including served as its Vice President of Business Development from 1999 to 2001, President and Chief Operating Officer from 2001 to 2003 and President and Chief Executive Officer from 2003 to April 9, 2007. He served as a Vice President of External Affairs of Novartis Pharmaceuticals. He served as an Executive Director of Corporate Planning and Administration of Sandoz Canada Inc. He served as a Consultant of AEterna Zentaris Inc., since April 9, 2007. He served as Chairman of BIOQuebec. He has been a Director of Spectrum Pharmaceuticals, Inc. since March 27, 2012. He has been a Director of AEterna Laboratories Inc. since 2002. He has been a Director of Ceapro Inc. since September 11, 2007. He served as a Director of BIOQuebec. He served as a Director of Warnex Inc., from April 29, 2008 to June 29, 2011. He served as a Director of Æterna Zentaris Inc. from 2002 to April 9, 2007. He served as a Director of MDN Inc. since 1995. He holds Post-graduate degrees in Pharmacology (M.Sc.) and Administration (M.B.A) from the Université de Sherbrooke, as well as a Certificate in General Management from the London Business School, UK. Mr. Gagnon holds Directors Education Program at the Rotman School of Management of the University of Toronto.

CEO Compensation
  • Gilles's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Gilles's remuneration is about average for companies of similar size in United States of America.
Management Team

Gilles Gagnon

TITLE
CEO, President & Director
COMPENSATION
CA$555K
AGE
64
TENURE
6.9 yrs

Stacy Prefontaine

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$213K
TENURE
4.1 yrs
Board of Directors Tenure

Average tenure of the Ceapro board of directors in years:

8.2
Average Tenure
  • The tenure for the Ceapro board of directors is about average.
Board of Directors

Glenn Rourke

TITLE
Chairman of the Board
COMPENSATION
CA$35K
TENURE
4.7 yrs

Gilles Gagnon

TITLE
CEO, President & Director
COMPENSATION
CA$555K
AGE
64
TENURE
11.8 yrs

John Zupancic

TITLE
Independent Director
COMPENSATION
CA$30K
TENURE
21.4 yrs

Don Oborowsky

TITLE
Independent Director
COMPENSATION
CA$25K
TENURE
20.4 yrs

Will Li

TITLE
Director
COMPENSATION
CA$32K
AGE
55
TENURE
4.6 yrs

Ulrich Kosciessa

TITLE
Independent Director
COMPENSATION
CA$38K
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Ceapro's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ceapro has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CRPO.F News

Simply Wall St News

CRPO.F Company Info

Description

Ceapro Inc., a biotechnology company, engages in developing and commercializing functionally active ingredients in the United States, Canada, Germany, China, and internationally. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company’s products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, including Pressurized Gas eXpanded drying technology; new oat variety and technologies to enhance the content of avenanthramides; and CeaProve, a diabetes test meal to screen pre-diabetes and to confirm diabetes diagnosis. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Details
Name: Ceapro Inc.
CRPO.F
Exchange: OTCPK
Founded: 1997
CA$21,875,159
77,048,341
Website: http://www.ceapro.com
Address: Ceapro Inc.
7824 – 51 Avenue NW,
Edmonton,
Alberta, T6E 6W2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV CZO Class A Voting Common Shares TSX Venture Exchange CA CAD 22. Sep 1988
OTCPK CRPO.F Class A Voting Common Shares Pink Sheets LLC US USD 22. Sep 1988
DB 385 Class A Voting Common Shares Deutsche Boerse AG DE EUR 22. Sep 1988
Number of employees
Current staff
Staff numbers
0
Ceapro employees.
Industry
Specialty Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/17 00:19
End of day share price update: 2019/06/11 00:00
Last estimates confirmation: 2017/04/06
Last earnings filing: 2019/05/23
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.